Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Access Pharmaceuticals, Inc.
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
July 11th, 2008
ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access' Chief Scientific Officer -- Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells. Dr. Epenetos commented, "There is a growing body of evidence that indicates that tumor progression, dissemination and metastases result from cancer stem cells rather than the other cells which form the bulk of a cancer. As a result, therapies which attack these...
Source: Health Business Week (2008-07-11)
|
